[Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?].
Nielsen
Jørn Dalsgaard
JD
Amtssygehuset i Gentofte, Klinisk Biokemisk Afdeling, Københavns Amts Trombosecenter & Koagulationslaboratorium, Hellerup. joeda@gentoftehosp.kbhamt.dk
D000925:Anticoagulants / Q000008:administration & dosage*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects*; D001384:Azetidines / Q000008:administration & dosage*; D001596:Benzylamines; D017326:Clinical Trials, Phase III as Topic; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D000077425:Fondaparinux; D005998:Glycine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006801:Humans; D011134:Polysaccharides / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000517:prevention & control*; D011655:Pulmonary Embolism / Q000517:prevention & control; D013923:Thromboembolism / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; D011134:Polysaccharides; C109573:melagatran; C426686:ximelagatran; D000077425:Fondaparinux; D005998:Glycine